United Therapeutics Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über United Therapeutics Corp Unternehmen

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

United Therapeutics Corp Informationen



BörsenkürzelUTHR

Name des UnternehmensUnited Therapeutics Corp

IPO-datumJun 17, 1999

CEORothblatt (Martine A)

Anzahl der mitarbeiter1305

WertpapierartOrdinary Share

GeschäftsjahresendeJun 17

Addresse1000 Spring St

StadtSILVER SPRING

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl20910

Telefon13016089292

Websitehttps://www.unither.com/

BörsenkürzelUTHR

IPO-datumJun 17, 1999

CEORothblatt (Martine A)

Führungskräfte von United Therapeutics Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

--

Ms. Jan Malcolm

Director

270.00

-50.00%

Mr. Raymond C. (Ray) Kurzweil, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

Andere

16.60M

2.08%

Nach RegionUSD

Name

Umsatz

Anteil

United States

774.80M

96.91%

Rest of World

24.70M

3.09%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

Andere

16.60M

2.08%

Aktionärsstatistik

Aktualisiert: Mon, Nov 17

Aktionäre

Aktionärstypen

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

9.90%

The Vanguard Group, Inc.

9.65%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

Andere

66.24%

Aktionäre

Anteil

BlackRock Institutional Trust Company, N.A.

9.90%

The Vanguard Group, Inc.

9.65%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

Andere

66.24%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

42.29%

Investment Advisor/Hedge Fund

33.68%

Hedge Fund

13.61%

Research Firm

2.96%

Pension Fund

2.63%

Individual Investor

1.84%

Bank and Trust

1.42%

Sovereign Wealth Fund

1.29%

Venture Capital

0.46%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

1439

42.90M

99.63%

-3.07M

2025Q3

1348

44.10M

102.42%

-3.87M

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

BlackRock Institutional Trust Company, N.A.

4.26M

9.9%

-76.88K

-1.77%

Sep 30, 2025

The Vanguard Group, Inc.

4.40M

10.22%

-31.08K

-0.70%

Sep 30, 2025

Renaissance Technologies LLC

2.17M

5.05%

+54.30K

+2.56%

Sep 30, 2025

Avoro Capital Advisors LLC

2.02M

4.7%

-347.78K

-14.67%

Sep 30, 2025

State Street Investment Management (US)

1.92M

4.47%

-244.90K

-11.30%

Sep 30, 2025

Wellington Management Company, LLP

1.40M

3.25%

-44.16K

-3.06%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.25M

2.9%

+49.30K

+4.11%

Sep 30, 2025

AQR Capital Management, LLC

986.48K

2.29%

-286.68K

-22.52%

Sep 30, 2025

Darwin Global Management Ltd

748.55K

1.74%

+748.55K

--

Sep 30, 2025

Rothblatt (Martine A)

666.42K

1.55%

--

Dec 19, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

Simplify Health Care ETF

5.9%

Formidable Fortress ETF

4.22%

Franklin Genomic Advancements ETF

4.09%

First Trust NASDAQ Pharmaceuticals ETF

3.87%

Invesco Pharmaceuticals ETF

3.85%

Invesco Biotechnology & Genome ETF

3.82%

Invesco S&P MidCap Quality ETF

3.74%

Inspire Growth ETF

3.7%

VanEck Biotech ETF

3.58%

First Trust NYSE Arca Biotechnology Index Fund

3.4%

Simplify Health Care ETF

Anteil5.9%

Formidable Fortress ETF

Anteil4.22%

Franklin Genomic Advancements ETF

Anteil4.09%

First Trust NASDAQ Pharmaceuticals ETF

Anteil3.87%

Invesco Pharmaceuticals ETF

Anteil3.85%

Invesco Biotechnology & Genome ETF

Anteil3.82%

Invesco S&P MidCap Quality ETF

Anteil3.74%

Inspire Growth ETF

Anteil3.7%

VanEck Biotech ETF

Anteil3.58%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.4%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten